41554 blogs · [ { "id": "01a0da0c-a0c3-7294-b65b-aa4dc267e0e0", "title": "Did the Three Kings Deliver the MS Cure?", "url": "https://multiple-sclerosis-research.org/2026/09/did-the-three-kings-deliver-the-ms-cure/?utm_source=rss&utm_medium=rss&utm_campaign=did-the-three-kings-deliver-the-ms-cure", "published_at": "2026-09-25T08:31:34+00:00" }, { "id": "01a0da0c-a0c3-7294-b65b-aa4dc32504ed", "title": "Frexalimab for progressive MS?", "url": "https://multiple-sclerosis-research.org/2026/09/frexalimab-for-progressive-ms/?utm_source=rss&utm_medium=rss&utm_campaign=frexalimab-for-progressive-ms", "published_at": "2026-09-24T09:28:00+00:00" }, { "id": "01a0da0c-a0c3-7294-b65b-aa4dc39ddede", "title": "Detecting the Crap Gap", "url": "https://multiple-sclerosis-research.org/2026/09/detecting-the-crap-gap/?utm_source=rss&utm_medium=rss&utm_campaign=detecting-the-crap-gap", "published_at": "2026-09-23T08:57:00+00:00" }, { "id": "01a0da0c-a0c3-7294-b65b-aa4dc42dd56b", "title": "A tool to look at Repair", "url": "https://multiple-sclerosis-research.org/2026/09/a-tool-to-look-at-repair/?utm_source=rss&utm_medium=rss&utm_campaign=a-tool-to-look-at-repair", "published_at": "2026-09-22T09:20:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-066962877dbf", "title": "Can hand function be a main endpoint in trials. I f hope so", "url": "https://multiple-sclerosis-research.org/2026/09/can-hand-function-be-a-main-endpoint-in-trials-i-f-ing-hope-so/?utm_source=rss&utm_medium=rss&utm_campaign=can-hand-function-be-a-main-endpoint-in-trials-i-f-ing-hope-so", "published_at": "2026-09-21T09:48:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-06696311733d", "title": "Time for MSbase", "url": "https://multiple-sclerosis-research.org/2026/09/time-for-msbase/?utm_source=rss&utm_medium=rss&utm_campaign=time-for-msbase", "published_at": "2026-09-20T09:33:17+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-0669635cf1c4", "title": "Support the Original", "url": "https://multiple-sclerosis-research.org/2026/09/support-the-original/?utm_source=rss&utm_medium=rss&utm_campaign=support-the-original", "published_at": "2026-09-20T09:29:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-0669640aee97", "title": "Mesenchymal Stem Cells… Scraping the barrel to get something positive?", "url": "https://multiple-sclerosis-research.org/2026/09/mesenchymal-stem-cells-scraping-the-barrel-to-get-something-positive/?utm_source=rss&utm_medium=rss&utm_campaign=mesenchymal-stem-cells-scraping-the-barrel-to-get-something-positive", "published_at": "2026-09-19T09:00:47+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-066964bf65e0", "title": "Trigger Point…EBV activating MS", "url": "https://multiple-sclerosis-research.org/2026/09/trigger-point-ebv-activating-ms/?utm_source=rss&utm_medium=rss&utm_campaign=trigger-point-ebv-activating-ms", "published_at": "2026-09-18T09:38:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-0669652ae515", "title": "A trial to compare HSCT and alemtuzumab is needed…Are we dreaming?", "url": "https://multiple-sclerosis-research.org/2026/09/a-trial-to-compare-hsct-and-alemtuzumab-is-needed-are-we-dreaming/?utm_source=rss&utm_medium=rss&utm_campaign=a-trial-to-compare-hsct-and-alemtuzumab-is-needed-are-we-dreaming", "published_at": "2026-09-17T09:28:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-066965e69d20", "title": "Anti-CD20 and natalizumab and pregnancy", "url": "https://multiple-sclerosis-research.org/2026/09/anti-cd20-and-natalizumab-and-pregnancy/?utm_source=rss&utm_medium=rss&utm_campaign=anti-cd20-and-natalizumab-and-pregnancy", "published_at": "2026-09-16T06:00:23+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-0669662da09a", "title": "Into the Unknown-Ofatumumab", "url": "https://multiple-sclerosis-research.org/2026/09/into-the-unknown-ofatumumab/?utm_source=rss&utm_medium=rss&utm_campaign=into-the-unknown-ofatumumab", "published_at": "2026-09-15T09:00:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-06696639d4b3", "title": "Increased intervals with rituximab maintains benefit.", "url": "https://multiple-sclerosis-research.org/2026/09/increased-intervals-with-rituximab-maintains-benefit/?utm_source=rss&utm_medium=rss&utm_campaign=increased-intervals-with-rituximab-maintains-benefit", "published_at": "2026-09-14T09:28:00+00:00" }, { "id": "01a0c6a1-d9ee-7185-b362-066966cdda1b", "title": "Stem cell transplants and atrophy", "url": "https://multiple-sclerosis-research.org/2026/09/stem-cell-transplants-and-atrophy/?utm_source=rss&utm_medium=rss&utm_campaign=stem-cell-transplants-and-atrophy", "published_at": "2026-09-14T06:00:59+00:00" }, { "id": "01a09529-52a2-7034-a08b-4b22f679ef47", "title": "Drug Cost and access", "url": "https://multiple-sclerosis-research.org/2026/09/drug-cost-and-access/?utm_source=rss&utm_medium=rss&utm_campaign=drug-cost-and-access", "published_at": "2026-09-12T09:43:32+00:00" }, { "id": "01a09529-52a2-7034-a08b-4b22f778dce8", "title": "T-time Part II. Someone do it & put me out of my misery", "url": "https://multiple-sclerosis-research.org/2026/09/t-time-part-ii-someone-do-it-put-me-out-of-my-misery/?utm_source=rss&utm_medium=rss&utm_campaign=t-time-part-ii-someone-do-it-put-me-out-of-my-misery", "published_at": "2026-09-12T09:03:00+00:00" }, { "id": "01a09529-52a2-7034-a08b-4b22f7c6abbd", "title": "T-time-Part I. The Gaulet needs to thrown down. Get rid of the T’s get rid of the MS? P.S. The naff B cell nibbling idea should bite the dust!", "url": "https://multiple-sclerosis-research.org/2026/09/t-time-part-i-the-gaulet-needs-to-thrown-down-get-rid-of-the-ts-get-rid-of-the-ms-p-s-the-naff-b-cell-nibbling-idea-should-bite-the-dust/?utm_source=rss&utm_medium=rss&utm_campaign=t-time-part-i-the-gaulet-needs-to-thrown-down-get-rid-of-the-ts-get-rid-of-the-ms-p-s-the-naff-b-cell-nibbling-idea-should-bite-the-dust", "published_at": "2026-09-11T09:00:00+00:00" }, { "id": "01a09529-52a2-7034-a08b-4b22f804e036", "title": "Tolerance induction in humans", "url": "https://multiple-sclerosis-research.org/2026/09/tolerance-induction-in-humans/?utm_source=rss&utm_medium=rss&utm_campaign=tolerance-induction-in-humans", "published_at": "2026-09-11T07:00:35+00:00" }, { "id": "01a08cca-3fd8-7160-afc4-df0d67b35420", "title": "Too much CD20 not enough BTKi", "url": "https://multiple-sclerosis-research.org/2026/09/too-much-cd20-not-enough-btki/?utm_source=rss&utm_medium=rss&utm_campaign=too-much-cd20-not-enough-btki", "published_at": "2026-09-10T09:44:48+00:00" }, { "id": "01a08cca-3fd8-7160-afc4-df0d687d193a", "title": "Neuromyelitis Optica gets another target", "url": "https://multiple-sclerosis-research.org/2026/09/neuromyelitis-optica-gets-another-target/?utm_source=rss&utm_medium=rss&utm_campaign=neuromyelitis-optica-gets-another-target", "published_at": "2026-09-10T09:05:12+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b692a8df1", "title": "Will we get a new excersise plan for Manchester or London?", "url": "https://multiple-sclerosis-research.org/2026/09/will-we-get-a-new-excersise-plan-for-manchester-or-london/?utm_source=rss&utm_medium=rss&utm_campaign=will-we-get-a-new-excersise-plan-for-manchester-or-london", "published_at": "2026-09-09T09:00:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6a10055a", "title": "Q&A Septemeber", "url": "https://multiple-sclerosis-research.org/2026/09/qa-septemeber/?utm_source=rss&utm_medium=rss&utm_campaign=qa-septemeber", "published_at": "2026-09-08T09:49:27+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6af3051c", "title": "Models for personalised Dosing?", "url": "https://multiple-sclerosis-research.org/2026/09/models-for-personalised-dosing/?utm_source=rss&utm_medium=rss&utm_campaign=models-for-personalised-dosing", "published_at": "2026-09-08T09:01:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6b6c48f1", "title": "Take it with a pinch-No thank you", "url": "https://multiple-sclerosis-research.org/2026/09/take-it-with-a-pinch-no-thank-you/?utm_source=rss&utm_medium=rss&utm_campaign=take-it-with-a-pinch-no-thank-you", "published_at": "2026-09-07T09:50:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6be97a9e", "title": "CAR-T Made easy", "url": "https://multiple-sclerosis-research.org/2026/09/car-t-made-easy/?utm_source=rss&utm_medium=rss&utm_campaign=car-t-made-easy", "published_at": "2026-09-06T09:44:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6c9fbce5", "title": "Changing microglia from the blood as you age.", "url": "https://multiple-sclerosis-research.org/2026/09/changing-microglia-from-the-blood-as-you-age/?utm_source=rss&utm_medium=rss&utm_campaign=changing-microglia-from-the-blood-as-you-age", "published_at": "2026-09-05T09:04:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6d5b9e43", "title": "Trial of the Year…Oh Please", "url": "https://multiple-sclerosis-research.org/2026/09/trial-of-the-year-oh-please/?utm_source=rss&utm_medium=rss&utm_campaign=trial-of-the-year-oh-please", "published_at": "2026-09-04T15:00:30+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6d72e063", "title": "Diagnosing MS early, accurately & efficiently", "url": "https://multiple-sclerosis-research.org/2026/09/diagnosing-ms-early-accurately-efficiently/?utm_source=rss&utm_medium=rss&utm_campaign=diagnosing-ms-early-accurately-efficiently", "published_at": "2026-09-03T06:00:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6df8e549", "title": "Biomarker BS…OK it’s disappointing", "url": "https://multiple-sclerosis-research.org/2026/09/biomarker-bs-ok-its-disappointing/?utm_source=rss&utm_medium=rss&utm_campaign=biomarker-bs-ok-its-disappointing", "published_at": "2026-09-02T05:17:00+00:00" }, { "id": "01a087aa-7d83-7234-8f06-b44b6eef5444", "title": "Does MS become a viral disease and not an autoimmune condition..virus Shedding before MS", "url": "https://multiple-sclerosis-research.org/2026/09/does-ms-become-a-viral-disease-and-not-an-autoimmune-condition-virus-shedding-before-ms/?utm_source=rss&utm_medium=rss&utm_campaign=does-ms-become-a-viral-disease-and-not-an-autoimmune-condition-virus-shedding-before-ms", "published_at": "2026-09-01T09:00:00+00:00" } ] posts Claim your blog

Back to multiple-sclerosis-research.org

Blog · corpus.blog/blogs/multiple-sclerosis-research.org/posts

multiple-sclerosis-research.org

multiple-sclerosis-research.org

2026

Did the Three Kings Deliver the MS Cure?original ↗

25 Sept 2026

Frexalimab for progressive MS?original ↗

24 Sept 2026

Detecting the Crap Gap original ↗

23 Sept 2026

A tool to look at Repair original ↗

22 Sept 2026

Can hand function be a main endpoint in trials. I f hope so original ↗

21 Sept 2026

Time for MSbase original ↗

20 Sept 2026

Support the Original original ↗

20 Sept 2026

Mesenchymal Stem Cells… Scraping the barrel to get something positive?original ↗

19 Sept 2026

Trigger Point…EBV activating MS original ↗

18 Sept 2026

A trial to compare HSCT and alemtuzumab is needed…Are we dreaming?original ↗

17 Sept 2026

Anti-CD20 and natalizumab and pregnancy original ↗

16 Sept 2026

Into the Unknown-Ofatumumab original ↗

15 Sept 2026

Increased intervals with rituximab maintains benefit.original ↗

14 Sept 2026

Stem cell transplants and atrophy original ↗

14 Sept 2026

Drug Cost and access original ↗

12 Sept 2026

T-time Part II. Someone do it & put me out of my misery original ↗

12 Sept 2026

T-time-Part I. The Gaulet needs to thrown down. Get rid of the T’s get rid of the MS? P.S. The naff B cell nibbling idea should bite the dust!original ↗

11 Sept 2026

Tolerance induction in humans original ↗

11 Sept 2026

Too much CD20 not enough BTKi original ↗

10 Sept 2026

Neuromyelitis Optica gets another target original ↗

10 Sept 2026

Will we get a new excersise plan for Manchester or London?original ↗

9 Sept 2026

Q&A Septemeber original ↗

8 Sept 2026

Models for personalised Dosing?original ↗

8 Sept 2026

Take it with a pinch-No thank you original ↗

7 Sept 2026

CAR-T Made easy original ↗

6 Sept 2026

Changing microglia from the blood as you age.original ↗

5 Sept 2026

Trial of the Year…Oh Please original ↗

4 Sept 2026

Diagnosing MS early, accurately & efficiently original ↗

3 Sept 2026

Biomarker BS…OK it’s disappointing original ↗

2 Sept 2026

Does MS become a viral disease and not an autoimmune condition..virus Shedding before MS original ↗

1 Sept 2026